Noticias

Is Joint Pain an Unavoidable Menopausal Hurdle? This Natural Compound May Hit the "Brakes"

2026-03-06 10:36:54

Visitas:0

Among women over 50, the prevalence of osteoarthritis is as high as 22%, nearly double that of men in the same age group.Who is the primary culprit? Estrogen.The sharp decline in estrogen after menopa

Among women over 50, the prevalence of osteoarthritis is as high as 22%, nearly double that of men in the same age group.

Who is the primary culprit? Estrogen.

The sharp decline in estrogen after menopause means the articular cartilage loses its lubrication and protection, accelerating wear and tear. However, hormone replacement therapy carries risks, including breast cancer, leaving many in a dilemma.

This is where S-Equol, the "final metabolite" of soy, has garnered scientific attention.

It is more stable and bioactive than common soy isoflavones. But here's the catch: not everyone can produce it. Only 25%-30% of Western populations can produce S-Equol after consuming soy products; the rate is slightly higher in Asia, but still only 50%-60%.

So, what about direct supplementation? Can S-Equol help us cross the hurdle of menopausal joint pain?

The research suggests: Yes, it can, and the evidence is steadily accumulating.

A research team has, for the first time, systematically confirmed in an animal model that S-Equol supplementation (at 2 mg/kg, equivalent to the converted human recommended daily dose) has a protective effect against menopausal osteoarthritis of varying severity. Let's re-examine the chain of evidence:

Step 1: Improving the Systemic Metabolic Environment
Menopausal women often face weight gain and dyslipidemia, which can exacerbate joint burden. The study showed that S-Equol reduced body weight (Table 1) and serum triglyceride levels (Figure 1B) in OVX rats – effectively lightening the load on the joints from the "periphery."

image

Step 2: Protecting Articular Cartilage Structure
Visual observation and tissue staining provide the most direct evidence. After S-Equol supplementation, the articular cartilage surface in rats appeared smoother, the loss of Safranin O staining (representing proteoglycan content in cartilage) was reduced, and the OARSI histological score was significantly lowered (Figure 2A, 2B, 2C) – indicating repair at the "battlefield" site itself.

image

Step 3: Inhibiting Bone Resorption, Stabilizing Subchondral Bone
Osteoarthritis isn't just about cartilage; abnormal metabolism in the subchondral bone is equally critical. S-Equol reduced levels of bone resorption markers CTX-I and NTX-I (Figure 3B, 3C), helping to stabilize the subchondral bone microenvironment.

image

Step 4: Reducing Cartilage Matrix Degradation
The decrease in cartilage degradation markers HA and PIINP (Figure 4A, 4B) indicates that the loss of cartilage matrix is curbed. Behind this lies the inhibitory effect of S-Equol on matrix metalloproteinases (MMP-1, MMP-3, MMP-13) (Figure 5A, 5B, 5C) – the very enzymes responsible for degrading cartilage collagen and proteoglycans.

image

Step 5: Scavenging Oxidative Stress
Oxidative stress is one of the drivers accelerating joint aging after menopause. S-Equol reduced levels of H₂O₂ and NO (Figure 6A, 6B), with a more pronounced effect, particularly in the severe osteoarthritis group, suggesting it mitigates cellular damage at its source.

image

From body weight and blood lipids to cartilage structure, degradative enzyme activity, and oxidative stress – S-Equol hits the "brakes" on menopausal osteoarthritis progression at multiple points.

Of course, whether the results from animal studies can be fully replicated in humans requires validation through more clinical research. But at least the pathway is clear: For women unable to produce sufficient S-Equol naturally (70%-75% in Western populations, 40%-50% in Asia), direct S-Equol supplementation might be a worthwhile option to consider.

This study extends its protective scope from osteoporosis to osteoarthritis – from bone to joint, this piece of the soy "puzzle" is gradually being filled.

In the future, we look forward to more research answering the question: Can S-Equol become a "daily guardian" for joint health in menopausal women? At least for now, it has presented a promising and hopeful answer.

Source:
Hu, Yu-Chen, Tzu-Ching Huang, Li-Wen Huang, Hsiao-Ling Cheng, Bau-Shan Hsieh, and Kee-Lung Chang. 2024. "S-Equol Ameliorates Menopausal Osteoarthritis in Rats through Reducing Oxidative Stress and Cartilage Degradation" Nutrients 16, no. 14: 2364. https://doi.org/10.3390/nu16142364


Autor: admitir
En la era de los coches definidos por software, cuando los límites entre ceros se difuminan
¿Existe algún buen método para la selección y compra de productos de autopartes? ¿Cómo comprar las piezas de automóvil más adecuadas y rentables? Aquí, recomiendo las siguientes habilidades para ayudarte a elegir
Mantenga presionada la imagen para guardar/compartir

Desde su creación, la empresa se ha adherido a un enfoque centrado en las personas con un enfoque central en la salud humana y un compromiso con la innovación continua como ventaja competitiva. Se ha concentrado constantemente en la investigación científica de vanguardia en la industria global de la salud y el bienestar.

Navegación del sitio

Contacto

Dirección: Edificio 21, Yinfeng International Bio-city, No. 1177 Chunlan Road, Jinan, Shandong China Código postal: 250100 Teléfono de contacto de comercio nacional: +86-18980869808 +86-19854163113 Correo electrónico: info@yltnutra.com Teléfono de contacto del departamento de comercio internacional: +86-17778451219 +86-18980869808 Correo electrónico:jennyy@yltnutra.com

Suscríbete a nosotros

Ingrese su dirección de correo electrónico para nuestra lista de correo para mantenerse actualizado.

© 2026Shandong Yuanlitai Medical Technology Co. Ltd. . All rights reserved     Lu PCI No. 2022033305 mapa del sitio

Sistema de atención al cliente en línea.